Novartis oncology deal adds to pipeline, shares hold near Swiss high

Novartis expands its oncology discovery pipeline with a potential USD 1.9 billion partnership and trades on SIX close to its 52?week high, while consensus still points to upside for the stock.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 21:19.

Novartis (CH0012005267) is adding scale to its oncology research pipeline with a fresh discovery partnership. The Swiss blue chip, listed on SIX and part of the SMI, trades only a few percent below its 52-week high on the Zurich exchange, underscoring solid investor confidence as of late according to market data from the Financial Times.FT markets overview for Novartis

Oncology discovery deal with Antares

On June 24, 2026 Antares Therapeutics announced that it had entered into a discovery, development and commercialization agreement with Novartis focused on first-in-class oncology therapies. The US biotech disclosed potential deal value of up to USD 1.9 billion, including milestones and royalties tied to multiple programs in solid tumors and hematologic cancers.Reuters coverage of the Antares-Novartis deal

Novartis will initially fund discovery work at Antares laboratories and has secured global rights to candidates emerging from the collaboration, subject to clinical success and regulatory approvals. Antares noted in its statement that Novartis brings extensive oncology development and commercialization capabilities to the partnership, particularly in targeted therapies and cell-based treatments.Antares Therapeutics press release on the Novartis collaboration

Analyst stance and consensus on the stock

Analysts remain broadly constructive on Novartis shares after the latest pipeline move. Deutsche Bank reiterated its Buy rating on the stock this week, according to MarketScreener, highlighting the combination of a defensive prescription portfolio and incremental oncology optionality from external partnerships.MarketScreener note on Deutsche Bank's Buy rating for Novartis

TradingView data show that the Novartis shares currently change hands at around 125.88 Swiss francs on SIX, roughly 4 percent below the 52-week high of 131.00 francs set in late February 2026. The same data set reports a range of analyst target prices between approximately 97.71 and 143.99 francs, illustrating a spread of views but a skew towards upside versus current levels.TradingView overview and analyst target range for NOVN

How Novartis makes its money

Novartis generates the bulk of its revenue from prescription pharmaceuticals across key therapeutic areas such as oncology, immunology and neuroscience. A flagship product is Cosentyx, a monoclonal antibody used in indications including psoriasis and psoriatic arthritis, which has become a multi-billion-dollar franchise with steady demand in major markets, according to company disclosures.Novartis product information on Cosentyx

Where the shares trade today

The Novartis shares (CH0012005267) trade on SIX Swiss Exchange at 125.88 Swiss francs as of 2026-06-25, 16:00, based on TradingView quote data for the NOVN ticker. The stock is also available via secondary listings such as Xetra, where it is quoted in euros for German investors.

Key data on the Novartis shares

• Company: Novartis AG
• ISIN: CH0012005267
• WKN: 904278
• Ticker: NOVN
• Trading venue: SIX Swiss Exchange (primary listing)
• Price (as of 2026-06-25, 16:00): 125.88 CHF
• Market cap: approximately 268 billion CHF (as of 2026-06-25, based on SIX data and FX assumptions)
• Sector / industry: Health Care / Pharmaceuticals
• Index membership: SMI, STOXX Europe 50
• Next earnings date: 2026-07-21

Disclaimer: This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Historical data and analyst opinions are not a guarantee of future performance. Investors should conduct their own research or consult a professional advisor before making investment decisions.